Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program

Core Insights - Nasus Pharma has entered into a strategic collaboration with Aptar, a leading global manufacturer of drug delivery systems, to enhance the clinical and commercial development of its intranasal powder epinephrine product candidate, NS002 [1][2] Group 1: Collaboration Details - The collaboration provides Nasus Pharma with access to Aptar's proven Unit Dose System technology, which will support the development and commercialization of NS002 [2] - This partnership aims to leverage Aptar's regulatory pathways, manufacturing capabilities, and supply chain to accelerate NS002's market entry while minimizing development risks [2] Group 2: Product Information - NS002 is being developed as a needle-free alternative to traditional epinephrine autoinjectors for patients experiencing anaphylaxis, focusing on rapid drug delivery in emergency situations [3] - The proprietary powder-based intranasal (PBI) technology is designed for quick absorption through the nasal cavity, utilizing uniform spherical powder particles for enhanced dispersion and absorption compared to liquid-based products [3]